287 related articles for article (PubMed ID: 30840888)
1. APOBEC Mutagenesis and Copy-Number Alterations Are Drivers of Proteogenomic Tumor Evolution and Heterogeneity in Metastatic Thoracic Tumors.
Roper N; Gao S; Maity TK; Banday AR; Zhang X; Venugopalan A; Cultraro CM; Patidar R; Sindiri S; Brown AL; Goncearenco A; Panchenko AR; Biswas R; Thomas A; Rajan A; Carter CA; Kleiner DE; Hewitt SM; Khan J; Prokunina-Olsson L; Guha U
Cell Rep; 2019 Mar; 26(10):2651-2666.e6. PubMed ID: 30840888
[TBL] [Abstract][Full Text] [Related]
2. FHIT loss-induced DNA damage creates optimal APOBEC substrates: Insights into APOBEC-mediated mutagenesis.
Waters CE; Saldivar JC; Amin ZA; Schrock MS; Huebner K
Oncotarget; 2015 Feb; 6(5):3409-19. PubMed ID: 25401976
[TBL] [Abstract][Full Text] [Related]
3. Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors.
Middlebrooks CD; Banday AR; Matsuda K; Udquim KI; Onabajo OO; Paquin A; Figueroa JD; Zhu B; Koutros S; Kubo M; Shuin T; Freedman ND; Kogevinas M; Malats N; Chanock SJ; Garcia-Closas M; Silverman DT; Rothman N; Prokunina-Olsson L
Nat Genet; 2016 Nov; 48(11):1330-1338. PubMed ID: 27643540
[TBL] [Abstract][Full Text] [Related]
4. APOBEC Enzymes: Mutagenic Fuel for Cancer Evolution and Heterogeneity.
Swanton C; McGranahan N; Starrett GJ; Harris RS
Cancer Discov; 2015 Jul; 5(7):704-12. PubMed ID: 26091828
[TBL] [Abstract][Full Text] [Related]
5. Deep multi-region whole-genome sequencing reveals heterogeneity and gene-by-environment interactions in treatment-naive, metastatic lung cancer.
Leong TL; Gayevskiy V; Steinfort DP; De Massy MR; Gonzalez-Rajal A; Marini KD; Stone E; Chin V; Havryk A; Plit M; Irving LB; Jennings BR; McCloy RA; Jayasekara WSN; Alamgeer M; Boolell V; Field A; Russell PA; Kumar B; Gough DJ; Szczepny A; Ganju V; Rossello FJ; Cain JE; Papenfuss AT; Asselin-Labat ML; Cowley MJ; Watkins DN
Oncogene; 2019 Mar; 38(10):1661-1675. PubMed ID: 30348992
[TBL] [Abstract][Full Text] [Related]
6. Addressing the benefits of inhibiting APOBEC3-dependent mutagenesis in cancer.
Petljak M; Green AM; Maciejowski J; Weitzman MD
Nat Genet; 2022 Nov; 54(11):1599-1608. PubMed ID: 36280735
[TBL] [Abstract][Full Text] [Related]
7. Association of a germline copy number polymorphism of APOBEC3A and APOBEC3B with burden of putative APOBEC-dependent mutations in breast cancer.
Nik-Zainal S; Wedge DC; Alexandrov LB; Petljak M; Butler AP; Bolli N; Davies HR; Knappskog S; Martin S; Papaemmanuil E; Ramakrishna M; Shlien A; Simonic I; Xue Y; Tyler-Smith C; Campbell PJ; Stratton MR
Nat Genet; 2014 May; 46(5):487-91. PubMed ID: 24728294
[TBL] [Abstract][Full Text] [Related]
8. APOBEC mutagenesis is tightly linked to the immune landscape and immunotherapy biomarkers in head and neck squamous cell carcinoma.
Faden DL; Ding F; Lin Y; Zhai S; Kuo F; Chan TA; Morris LG; Ferris RL
Oral Oncol; 2019 Sep; 96():140-147. PubMed ID: 31422205
[TBL] [Abstract][Full Text] [Related]
9. Integrative genomic analyses of APOBEC-mutational signature, expression and germline deletion of APOBEC3 genes, and immunogenicity in multiple cancer types.
Chen Z; Wen W; Bao J; Kuhs KL; Cai Q; Long J; Shu XO; Zheng W; Guo X
BMC Med Genomics; 2019 Sep; 12(1):131. PubMed ID: 31533728
[TBL] [Abstract][Full Text] [Related]
10. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers.
Roberts SA; Lawrence MS; Klimczak LJ; Grimm SA; Fargo D; Stojanov P; Kiezun A; Kryukov GV; Carter SL; Saksena G; Harris S; Shah RR; Resnick MA; Getz G; Gordenin DA
Nat Genet; 2013 Sep; 45(9):970-6. PubMed ID: 23852170
[TBL] [Abstract][Full Text] [Related]
11. Genomic, transcriptomic, and viral integration profiles associated with recurrent/metastatic progression in high-risk human papillomavirus cervical carcinomas.
Liu JJ; Ho JY; Lee JE; Hur SY; Yoo J; Kim KR; Ryu D; Kim TM; Choi YJ
Cancer Med; 2020 Nov; 9(21):8243-8257. PubMed ID: 33017516
[TBL] [Abstract][Full Text] [Related]
12. APOBEC mediated mutagenesis drives genomic heterogeneity in endometriosis.
Revathidevi S; Nakaoka H; Suda K; Fujito N; Munirajan AK; Yoshihara K; Enomoto T; Inoue I
J Hum Genet; 2022 Jun; 67(6):323-329. PubMed ID: 35017684
[TBL] [Abstract][Full Text] [Related]
13. Germline APOBEC3B deletion is associated with breast cancer risk in an Asian multi-ethnic cohort and with immune cell presentation.
Wen WX; Soo JS; Kwan PY; Hong E; Khang TF; Mariapun S; Lee CS; Hasan SN; Rajadurai P; Yip CH; Mohd Taib NA; Teo SH
Breast Cancer Res; 2016 May; 18(1):56. PubMed ID: 27233495
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Mass Spectrometry to Interrogate Proteomic Heterogeneity in Metastatic Lung Adenocarcinoma and Validate a Novel Somatic Mutation CDK12-G879V.
Zhang X; Nguyen KD; Rudnick PA; Roper N; Kawaler E; Maity TK; Awasthi S; Gao S; Biswas R; Venugopalan A; Cultraro CM; Fenyö D; Guha U
Mol Cell Proteomics; 2019 Apr; 18(4):622-641. PubMed ID: 30617155
[TBL] [Abstract][Full Text] [Related]
15. Loss of SYNCRIP unleashes APOBEC-driven mutagenesis, tumor heterogeneity, and AR-targeted therapy resistance in prostate cancer.
Li X; Wang Y; Deng S; Zhu G; Wang C; Johnson NA; Zhang Z; Tirado CR; Xu Y; Metang LA; Gonzalez J; Mukherji A; Ye J; Yang Y; Peng W; Tang Y; Hofstad M; Xie Z; Yoon H; Chen L; Liu X; Chen S; Zhu H; Strand D; Liang H; Raj G; He HH; Mendell JT; Li B; Wang T; Mu P
Cancer Cell; 2023 Aug; 41(8):1427-1449.e12. PubMed ID: 37478850
[TBL] [Abstract][Full Text] [Related]
16. Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Yoshimura K; Inoue Y; Karayama M; Tsuchiya K; Mori K; Suzuki Y; Iwashita Y; Kahyo T; Kawase A; Tanahashi M; Ogawa H; Yokomura K; Inui N; Funai K; Shinmura K; Niwa H; Suda T; Sugimura H
Lung Cancer; 2019 Aug; 134():202-209. PubMed ID: 31319982
[TBL] [Abstract][Full Text] [Related]
17. APOBEC3B and APOBEC mutational signature as potential predictive markers for immunotherapy response in non-small cell lung cancer.
Wang S; Jia M; He Z; Liu XS
Oncogene; 2018 Jul; 37(29):3924-3936. PubMed ID: 29695832
[TBL] [Abstract][Full Text] [Related]
18. Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer.
Zhang Y; Delahanty R; Guo X; Zheng W; Long J
Hum Genomics; 2015 Dec; 9():34. PubMed ID: 26682542
[TBL] [Abstract][Full Text] [Related]
19. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
[No Abstract] [Full Text] [Related]
20. Spatial and temporal diversity in genomic instability processes defines lung cancer evolution.
de Bruin EC; McGranahan N; Mitter R; Salm M; Wedge DC; Yates L; Jamal-Hanjani M; Shafi S; Murugaesu N; Rowan AJ; Grönroos E; Muhammad MA; Horswell S; Gerlinger M; Varela I; Jones D; Marshall J; Voet T; Van Loo P; Rassl DM; Rintoul RC; Janes SM; Lee SM; Forster M; Ahmad T; Lawrence D; Falzon M; Capitanio A; Harkins TT; Lee CC; Tom W; Teefe E; Chen SC; Begum S; Rabinowitz A; Phillimore B; Spencer-Dene B; Stamp G; Szallasi Z; Matthews N; Stewart A; Campbell P; Swanton C
Science; 2014 Oct; 346(6206):251-6. PubMed ID: 25301630
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
